The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
NCT01847313 on ClinicalTrials.gov · last registry update 2019-02-08
A small phase 3 — 20 participants, against a typical 424. The sponsor logged completion for November 2015. Primary outcome, as filed: MCP-1:Creatinine Ratio in Urine. liraglutide is approved in the US, but not for diabetic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Karl Neff
- Sponsor type
- Other
- Enrollment
- 20
- Started
- 2013-04
- Primary completion
- 2015-11 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
MCP-1:Creatinine Ratio in Urine
Conditions studied
Diabetic Kidney Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.